KalVista Pharmaceuticals to Present at Stifel Healthcare Conference
November 08 2017 - 7:30AM
Business Wire
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today
announced that it will participate in a fireside chat at the Stifel
Healthcare Conference on Wednesday, November 15, 2017, at 8:00 a.m.
EST in New York City.
A live webcast of the presentation may be accessed on the
Investors section of the Company’s website at www.kalvista.com. An
audio archive will be available on KalVista’s website for 30 days
following the presentation.
About KalVista Pharmaceuticals, Inc.KalVista
Pharmaceuticals, Inc. is a pharmaceuticals company focused on the
discovery, development, and commercialization of small molecule
protease inhibitors for diseases with significant unmet need. The
initial focus is on inhibitors of plasma kallikrein, which is an
important component of the body’s inflammatory response and which,
in excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of
novel, small molecule plasma kallikrein inhibitors initially
targeting hereditary angioedema (HAE) and diabetic macular edema
(DME). The Company has created a structurally diverse portfolio of
oral plasma kallikrein inhibitors from which it plans to select
multiple drug candidates to advance into clinical trials for HAE.
KalVista’s most advanced program, an intravitreally administered
plasma kallikrein inhibitor known as KVD001, has successfully
completed its first-in-human study in patients with DME and is
being prepared for Phase 2 studies in 2017.
For more information, please visit www.kalvista.com.
Forward-Looking StatementsThis press release contains
"forward-looking" statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "goal," "seek," "believe,"
"project," "estimate," "expect," "strategy," "future," "likely,"
"may," "should," "will" and similar references to future periods.
These statements are subject to numerous risks and uncertainties
that could cause actual results to differ materially from what we
expect. Examples of forward-looking statements include, among
others, available funding and future clinical trial timing and
results. Further information on potential risk factors that could
affect our business and its financial results are detailed in the
annual report on Form 10-K filed on July 27, 2017, our most recent
Quarterly Report on Form 10-Q, and other reports as filed from time
to time with the Securities and Exchange Commission. We
undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171108005107/en/
KalVista Pharmaceuticals, Inc.Leah Monteiro,
857-999-0808Director, Corporate Communications & Investor
Relationsleah.monteiro@kalvista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Mar 2024 to Apr 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Apr 2023 to Apr 2024